07:00 , Apr 15, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) jumped $5.13 (64%) to $13.10 on Thursday after announcing that FDA said existing data, including a single Phase III trial, were sufficient to support an NDA for pimavanserin to...
00:34 , Apr 11, 2013 |  BC Extra  |  Financial News

VistaGen to raise $36M from Bergamo

VistaGen Therapeutics Inc. (OTCBB:VSTA) plans to raise $36 million through the sale of 72 million shares at $0.50 in a private placement to holding company Bergamo Acquisition Corp. (Pink:BGMO). The price is a 34% discount...